摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-Hydroxy-3-propyl-4-(4-bromomethylphenylmethoxy)phenyl]ethanone | 79557-61-2

中文名称
——
中文别名
——
英文名称
1-[2-Hydroxy-3-propyl-4-(4-bromomethylphenylmethoxy)phenyl]ethanone
英文别名
1-[4-[[4-(bromomethyl)phenyl]methoxy]-2-hydroxy-3-propylphenyl]ethanone
1-[2-Hydroxy-3-propyl-4-(4-bromomethylphenylmethoxy)phenyl]ethanone化学式
CAS
79557-61-2
化学式
C19H21BrO3
mdl
——
分子量
377.278
InChiKey
WSZXIUZJPOSXHB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    23
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-[2-Hydroxy-3-propyl-4-(4-bromomethylphenylmethoxy)phenyl]ethanone二甲基亚砜 为溶剂, 生成 1-[2-Hydroxy-3-propyl-4-(4-cyanomethylphenylmethoxy)phenyl]ethanone
    参考文献:
    名称:
    Tetrazolyl compounds and their use as anti allergic agents
    摘要:
    式##STR1##中的化合物,其中R.sub.1、R.sub.2和R.sub.3分别独立地选自H、OH、C.sub.1-C.sub.4烷基、R.sub.4 --CO和卤素,其中R.sub.4是C.sub.1-C.sub.4烷基;R.sub.5和R.sub.6分别独立地选自H、C.sub.1-C.sub.4烷基和可选择取代的苯基;R.sub.7是含有1至4个碳原子的烷基基团,可选地含有取代或未取代的苯基团;p为0或1;Z为1H-四唑-5-基或-CN基;以及其盐,可通过在有机溶剂中以40℃至120℃范围内的温度在碱的存在下,将式##STR2##的化合物与式##STR3##的化合物反应而制备,其中R.sub.1-R.sub.7如权利要求1所定义,并将所得化合物与碱金属氰化物或硫氰酸盐反应,可选地将所得化合物与叠氮离子的来源反应,以产生具有药理活性的式I的化合物,其中Z为1H-四唑-5-基。
    公开号:
    US04675334A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Tetrazolyl compounds and their use as anti allergic agents
    摘要:
    式##STR1##中的化合物,其中R.sub.1、R.sub.2和R.sub.3分别独立地选自H、OH、C.sub.1-C.sub.4烷基、R.sub.4 --CO和卤素,其中R.sub.4是C.sub.1-C.sub.4烷基;R.sub.5和R.sub.6分别独立地选自H、C.sub.1-C.sub.4烷基和可选择取代的苯基;R.sub.7是含有1至4个碳原子的烷基基团,可选地含有取代或未取代的苯基团;p为0或1;Z为1H-四唑-5-基或-CN基;以及其盐,可通过在有机溶剂中以40℃至120℃范围内的温度在碱的存在下,将式##STR2##的化合物与式##STR3##的化合物反应而制备,其中R.sub.1-R.sub.7如权利要求1所定义,并将所得化合物与碱金属氰化物或硫氰酸盐反应,可选地将所得化合物与叠氮离子的来源反应,以产生具有药理活性的式I的化合物,其中Z为1H-四唑-5-基。
    公开号:
    US04675334A1
点击查看最新优质反应信息

文献信息

  • Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them
    申请人:GLAXO GROUP LIMITED
    公开号:EP0028063A1
    公开(公告)日:1981-05-06
    Compounds are disclosed which are phenoxyalkoxyphenyl derivatives of general formula (I) wherein Y represents the group -A, -ZA or OZ1A where A represents a carboxylic acid group, a 5-1H-tetrazolyf ring or a N-5-1 H-tetrazolylcarboxamide group; Z represents a Ci-4 alkylene, C2-4 alkenylene or C2-4 alkynylene chain optionally substituted by one or more C1-3 alkyl groups and Z1 represents a C1-4 alkylene chain optionally substituted by one or more C1-3 alkyl groups; X represents a C1-10 carbon chain which may be saturated or unsaturated in the case of chains containing at least 4 carbon atoms, and may be substituted by a hydroxy group or by one or more C1-3 alkyl groups, which chain may be interrupted by a benzene ring which may be linked through its 1- and 2-, 1- and 3-, or 1- and 4-positions; R1 represents a hydrogen atom or a C1-6 alkyl group; R2 represents the group -COR6 where R6 represents a hydrogen atom, an aryl group or a C1-6 alkyl group which may be substituted by an aryl group; R3 represents a C1-6 alkyl group or a C3-6 alkenyl group; and R4 and R5 which may be the same or different, each represents a hydrogen atom, a halogen atom or a hydroxy, Ci-3 alkoxy, C1-6 alkyl, C3-C6 alkenyl, C1-3 alkanoyl, nitro or carboxylic acid group with the proviso that R4 and R5 cannot both be nitro, alkanoyl or carboxylic acid groups, and physologically acceptable salts thereof. The compounds are potent antagonists of the action of slow reacting substance of anaphylaxis and are thus indicated for use in the treatment of obstructive airways diseases such as asthma and hay fever and in skin afflictions.
    所公开的化合物是通式(I)的苯氧基烷氧基苯基衍生物 其中 Y 代表基团-A、-ZA 或 OZ1A,其中 A 代表羧酸基团、5-1H-四氮唑环或 N-5-1 H-四氮唑甲酰胺基团; Z 代表任选被一个或多个 C1-3 烷基取代的 Ci-4亚烷基、C2-4 亚烯基或 C2-4 亚炔基链,Z1 代表任选被一个或多个 C1-3 烷基取代的 C1-4 亚烷基链; X 代表 C1-10 碳链,可以是饱和的 或不饱和(如果链中至少含有 4 个碳原子),并可被羟基取代 或一个或多个 C1-3 烷基基团取代,该链可 可被一个苯环打断,该苯环可通过以下方式连接 1-位和 2-位、1-位和 3-位或 1-位和 4-位相连; R1 代表氢原子或 C1-6 烷基; R2 代表基团-COR6,其中 R6 代表氢原子、芳基或可被芳基取代的 C1-6 烷基; R3 代表 C1-6 烷基或 C3-6 烯基;以及 R4和R5可以相同或不同,各自代表氢原子、卤素原子或羟基、Ci-3烷氧基、C1-6烷基、C3-C6烯基、C1-3烷酰基、硝基或羧酸基团,但R4和R5不能都是硝基、烷酰基或羧酸基团,以及它们的物理上可接受的盐。 这些化合物是过敏性休克慢反应物质的强效拮抗剂,因此可用于治疗阻塞性呼吸道疾病,如哮喘和花粉症,以及皮肤病。
  • Novel pharmaceutical compounds and their preparation
    申请人:Lilly Industries Limited
    公开号:EP0132124A1
    公开(公告)日:1985-01-23
    Compounds of formula wherein R,, R2 and R3 are each independently selected from H, OH, C1-C4alkyl, R4-CO and halogen, where R. is C1-C4alkyl; R5 and R. are each independently selected from H, C1-C4alkyl and optionally-substituted phenyl; R7 is an alkylene group having from 1 to 4 carbon atoms, optionally containing a substituted or unsubstituted phenyl group; p or 0 or 1; and Z is a 1H-tetrazol-5-yl or a -CN group; and salts thereof, may be prepared by reacting a compound of formula. with a compound of formula wherein R1-R7 are as defined in claim 1, in an organic solvent at a temperature in the range of 40-120°C in the presence of a base, and reacting the resulting compound with an alkali metal cyanide orthiocyanate, and optionally reacting the resulting compound with a source of azide ions to produce pharmacologically active compounds of formula I wherein Z is 1H-tetrazol-5-yl.
    式中的化合物 其中 R、R2 和 R3 各自独立地选自 H、OH、C1-C4 烷基、R4-CO 和卤素,其中 R. 是 C1-C4 烷基;R5 和 R. 各自独立地选自 H、C1-C4 烷基和任选取代的苯基;R7 是具有 1 至 4 个碳原子的亚烷基,任选含有取代或未取代的苯基;p 或 0 或 1;以及 Z 是 1H-四唑-5-基或 -CN;及其盐可通过将式.A.化合物与式.B.化合物反应制备。 与式 其中 R1-R7 如权利要求 1 中所定义,在有机溶剂中,在碱存在下,在 40-120°C 的温度范围内,使所得化合物与碱金属氰化物原氰酸酯反应,并任选使所得化合物与叠氮离子源反应,以制得式 I 的药理活性化合物,其中 Z 为 1H-四唑-5-基。
  • STEGGIES, D. J.;VERGE, J. P.
    作者:STEGGIES, D. J.、VERGE, J. P.
    DOI:——
    日期:——
  • US4675334A
    申请人:——
    公开号:US4675334A
    公开(公告)日:1987-06-23
  • Tetrazolyl compounds and their use as anti allergic agents
    申请人:Lilly Industries Limited
    公开号:US04675334A1
    公开(公告)日:1987-06-23
    Compounds of formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each independently selected from H, OH, C.sub.1 -C.sub.4 alkyl, R.sub.4 --CO and halogen, where R.sub.4 is C.sub.1 -C.sub.4 alkyl; R.sub.5 and R.sub.6 are each independently selected from H, C.sub.1 -C.sub.4 alkyl and optionally-substituted phenyl; R.sub.7 is an alkylene group having from 1 to 4 carbon atoms, optionally containing a substituted or unsubstituted phenyl group; p is 0 or 1; and Z is a 1H-tetrazol-5-yl or a --CN group; and salts thereof, may be prepared by reacting a compound of formula. ##STR2## with a compound of formula ##STR3## wherein R.sub.1 -R.sub.7 are as defined in claim 1, in an organic solvent at a temperature in the range of 40.degree.-120.degree. C. in the presence of a base, and reacting the resulting compound with an alkali metal cyanide or thiocyanate, and optionally reacting the resulting compound with a source of azide ions to produce pharmacologically active compounds of formula I wherein Z is 1H-tetrazol-5-yl.
    式##STR1##中的化合物,其中R.sub.1、R.sub.2和R.sub.3分别独立地选自H、OH、C.sub.1-C.sub.4烷基、R.sub.4 --CO和卤素,其中R.sub.4是C.sub.1-C.sub.4烷基;R.sub.5和R.sub.6分别独立地选自H、C.sub.1-C.sub.4烷基和可选择取代的苯基;R.sub.7是含有1至4个碳原子的烷基基团,可选地含有取代或未取代的苯基团;p为0或1;Z为1H-四唑-5-基或-CN基;以及其盐,可通过在有机溶剂中以40℃至120℃范围内的温度在碱的存在下,将式##STR2##的化合物与式##STR3##的化合物反应而制备,其中R.sub.1-R.sub.7如权利要求1所定义,并将所得化合物与碱金属氰化物或硫氰酸盐反应,可选地将所得化合物与叠氮离子的来源反应,以产生具有药理活性的式I的化合物,其中Z为1H-四唑-5-基。
查看更多